Searchable abstracts of presentations at key conferences in endocrinology

ea0099p219 | Adrenal and Cardiovascular Endocrinology | ECE2024

11β-hydroxysteroid dehydrogenase type 1 inhibition unmasks multiple pathways that may mitigate the adverse effects of prescribed prednisolone

Pofi Riccardo , Coll Sergi , Othonos Nantia , Miller Hamish , Potter Tom , Escott Jane , Whittaker Andrew , Monfort Nuria , Ventura Rosa , Tomlinson Jeremy

Background: Prednisolone is the most commonly prescribed exogenous glucocorticoid(GC) and its use is frequently associated with the development of iatrogenic Cushing’s Syndrome. Once administered, prednisolone is rapidly converted to inactive prednisone by renal 11β-hydroxysteroid dehydrogenase type 2(11β-HSD2) and subsequently reactivated by 11β-HSD1. We have shown previously that 11β-HSD1 inhibition(with the selective 11β-HSD1 inhibitor, AZD4017...

ea0094p53 | Metabolism, Obesity and Diabetes | SFEBES2023

The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease

Colosimo Santo , Miller Hamish , Koutoukidis Dimitrios , Marjot Thomas , Tan Garry , Harman David , Aithal Guruprasad , Manousou Pinelopi , Forlano Roberta , Parker Richard , Sheridan David , Newsome Philip , Alazawi William , Cobbold Jeremy , Tomlinson Jeremy

Introduction: The relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes is well-established. However, the precise impact of glucose control on the severity and progression of NAFLD remains largely unexplored. Currently, none of the non-invasive scoring systems used to assess NAFLD severity incorporate glucose control markers, such as glycated hemoglobin (HbA1c).Methods: Data were collected fr...